EULAR 2025 Streamlines Rheumatoid Arthritis DMARD Management to Nine Recommendations
🔓 Free Teaser Guideline Rheumatology / Immunology Confirmatory Grade: Moderate
Smolen JS, Edwards CJ, Konzett V, et al.
Jun 13, 2026 · Published in: Annals of the Rheumatic Diseases
New EULAR guidelines redefine RA management with DMARDs.
Mirikizumab Sustains Four-Year Remission in Ulcerative Colitis Responders
Analysis Rheumatology / Immunology Confirmatory Grade: Low
Owens HN, Vázquez-Otero C, Arevalo M, et al.
Dec 7, 2026 · Published in: Human Vaccines & Immunotherapeutics
Also in Gastroenterology / Hepatology
Provider training can drive HPV vaccine uptake in young adults.
Subcutaneous Vedolizumab Holds Its Own Against Newer UC Therapies in Network Meta-Analysis
Analysis Rheumatology / Immunology Hypothesis-generating Grade: Low
Jiang J, Wojtowicz A, Uyei J, et al.
Oct 22, 2026 · Published in: BMC Gastroenterology
Also in Gastroenterology / Hepatology
Vedolizumab SC shines in efficacy and safety for ulcerative colitis.
BSR 2026 Polymyalgia Rheumatica Guideline: Bone Protection, Faster Tapers, Early Methotrexate, IL-6R Blockade
Guideline Rheumatology / Immunology Practice-changing Grade: Low
Toyoda T, Bhide S, Boland C, et al.
Oct 13, 2026 · Published in: Rheumatology (Oxford, England)
New PMR guideline supports safer glucocorticoid usage.
Interleukin Inhibitors in RA Raise Multiple Adverse-Event Signals
Analysis Rheumatology / Immunology Hypothesis-generating Grade: Low
Liu C, Li J, Huang C, et al.
Oct 8, 2026 · Published in: Frontiers in Immunology
Interleukin inhibitors for rheumatoid arthritis pose safety concerns.
DMARD De-escalation in Controlled RA Raises Flares, Not Safety Benefit
Analysis Rheumatology / Immunology Confirmatory Grade: Moderate
Zhang X, Pandey RK, Luo X, et al.
Oct 6, 2026 · Published in: Clinical and Translational Science
DMARD tapering raises flare risk in rheumatoid arthritis.
Rituximab Achieves Moderate Renal Response in Difficult Lupus Nephritis
Analysis Rheumatology / Immunology Confirmatory Grade: Low
Wang X, Liang S, Sun X, et al.
Sep 29, 2026 · Published in: Clinical and Translational Science
Also in Nephrology
Rituximab provides moderate renal benefits in hard-to-treat lupus nephritis cases.
Biologics and JAK inhibitors show efficacy in Crohn's-associated orofacial granulomatosis
Analysis Gastroenterology / Hepatology Hypothesis-generating Grade: Low
Lees RD, Patel P, Young G, et al.
Sep 22, 2026 · Published in: Journal of Crohn's & Colitis
Also in Rheumatology / Immunology
Biologics show promise for Crohn's disease with orofacial granulomatosis.
Telitacicept Add-On Boosts Renal Response in Proliferative Lupus Nephritis
Analysis Rheumatology / Immunology Hypothesis-generating Grade: Low
Tian T, Zhang A, Liu X, et al.
Sep 12, 2026 · Published in: Lupus Science & Medicine
Telitacicept enhances renal response in lupus nephritis.
Risankizumab in IBD: Effective but Evidence Uneven Across CD and UC
Analysis Gastroenterology / Hepatology Confirmatory Grade: Low
Afzal MW, Haseeb A, Ali U, et al.
Sep 1, 2026 · Published in: Medicine
Also in Rheumatology / Immunology
Risankizumab shows promise for challenging Crohn's and colitis cases.
Chronic Steroids and Age Predict JAK Inhibitor Discontinuation in RA
Analysis Rheumatology / Immunology Hypothesis-generating Grade: Low
Martinez-Molina C, Frade-Sosa B, Diaz-Torné C, et al.
Aug 31, 2026 · Published in: RMD Open
Glucocorticoids and age affect JAK inhibitor retention in RA.
Who Can Taper Abrocitinib? Early Response and Atopic Burden Predict Success
Analysis Rheumatology / Immunology Hypothesis-generating Grade: Low
Wang Y, Qin H, Gao Y, et al.
Aug 25, 2026 · Published in: Annals of Medicine
Can personalized abrocitinib dosing enhance atopic dermatitis management?
M2e Nanoparticle Vaccines: Rational Design for Universal Influenza A
Analysis Rheumatology / Immunology Hypothesis-generating Grade: Very Low
Bourlon L, Morlieras J, Marche PN, et al.
Aug 20, 2026 · Published in: Expert Review of Vaccines
M2e-based nanoparticles aim for universal influenza A protection.
Non-TNFi Biologics Linked to Lower PsA Risk
Analysis Rheumatology / Immunology
Kougkas N, Sotiriou E, Deligeorgakis D, et al.
Aug 12, 2026 · Published in: Rheumatology (Oxford, England)
Non-TNFi biologics may lower PsA risk in psoriasis.
Daratumumab plus anti-CD20 rescues refractory recurrent FSGS after transplant
Analysis Rheumatology / Immunology Hypothesis-generating Grade: Low
Leon J, Ducrocq E, Lafargue MC, et al.
Aug 9, 2026 · Published in: Kidney International Reports
Can dual antibody therapy offer a lifeline for transplant patients with recurrent FSGS?